MONTAGUE, PRINCE EDWARD ISLAND–(Marketwired – Dec. 18, 2014) (“Solarvest”), announces that the European patent office has allowed the claims of Solarvest’s “System, Method and Device for the Expression or Repression of Proteins” patent application and will grant the patent. The patent office in Korea has issued a similar approval.
These approvals are a significant milestone in Solarvest’s patent portfolio because this patent covers many areas of bioactive production (expression) in algae. The substantial scope of products covered includes proteins, antigens, and antibiotic like molecules as well as the Company’s clean hydrogen production technology and will provide the patent protection for future research & development programs.
This strengthens Solarvest’s existing patent portfolio and will enable Solarvest to operate unimpeded in several markets including numerous products targeted for human and animal health. This patent is particularly important because it relates to manipulation of cell processes in Algae and consequently improves Solarvest’s position with respect to the use of our unique algae strains as a ‘manufacturing platform’ to produce a diverse range of products ranging from vaccines and bioactive proteins to enzymes.
The Company continues to focus on launching its line of organic Omega-3 products.
View original article at: Solarvest Granted EU Patent for Algae Expression System